Lymphoma News

During the Lymphoma Research Foundation’s Denver Ask the Doctor About Lymphoma Program, lymphoma-expert and program host, John M. Burke, MD (Rocky Mountain Cancer Center), provided the following answer to this question: How can patients access innovative drug treatments when insurance…

A father and daughter’s story as both lymphoma survivors and each other’s caregivers, and their mission to empower themselves through education and connect with others at Lymphoma Research Foundation (LRF)’s North American Educational Forum on Lymphoma.

The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.

A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.

 On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…

Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).  This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.

Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.

Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is impacting women globally—leaving many questions for both patients and providers.

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).